On and effective June 15, 2022, VistaGen Therapeutics, Inc. (the Company) terminated the employment of H. Ralph Snodgrass, Ph.D., who served as the Company's President and Chief Scientific Officer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.86 USD | -1.03% | -0.51% | -24.71% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.71% | 105M | |
+18.33% | 125B | |
+14.34% | 109B | |
-2.58% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.48% | 16.64B | |
+0.04% | 13.45B | |
+23.28% | 11.32B |
- Stock Market
- Equities
- VTGN Stock
- News Vistagen Therapeutics, Inc.
- VistaGen Therapeutics, Inc. Terminates Employment of H. Ralph Snodgrass as President and Chief Scientific Officer